Emerging retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is generating considerable buzz within the healthcare community. Early clinical studies have demonstrated substantial decreases in physical weight and improvements in physiological markers for individuals with obesity . Scientists believe this unique approach ha… Read More